Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
283.34
0.00 (0.00%)
Alnylam Pharmaceuticals is a biopharmaceutical company focused on advancing innovative therapies using RNA interference (RNAi) technology to treat a range of genetic diseases
The company is dedicated to developing medicines that can selectively silence disease-causing genes, thereby addressing the underlying causes of conditions such as hereditary transthyretin-mediated amyloidosis and other rare disorders. With a strong commitment to research and development, Alnylam aims to deliver transformative treatments that improve patient outcomes and enhance quality of life for those affected by severe or life-threatening diseases.
Best performing large-cap stocks last week: Alnylam Pharma up 16%, Roku up 14%, Elbit Systems up 13%, Venture Global up 12%, Boeing up 11%. Are they in your portfolio?
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and Merck.
